MBK stands firm on offer price for AsiaPharm

The private equity company has no plans to raise its S$0.725 per share offer for the Chinese pharmaceutical firm, but reserves the right to revise the offer price if a competitive situation arises.

Quick Poll

Which risk do you perceive as being the most significant for EM investors today?

Previous polls ››

September 2016 Magazine
AsianInvestor Magazine

What's in this issue

Expanding ESG in Asia
Q&A: Jupai Holdings
The Brexit fallout for fund managers
Chinese hedge funds step offshore